Roxithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin, used to treat various bacterial infections. It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby blocking translocation of peptides. Roxithromycin offers improved acid stability and better oral bioavailability compared to erythromycin, with a longer half-life allowing for once or twice daily dosing.
Indications include:
∙ Respiratory tract infections (e.g., bronchitis, tonsillitis, pharyngitis)
∙ Skin and soft tissue infections
∙ Urogenital infections (e.g., non-gonococcal urethritis)
∙ Otitis media and sinusitis
Parent: Clarithromycin/ Erythromycin/ Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Parent: Roxithromycin
Impurities in roxithromycin arise from its chemical synthesis, fermentation-derived starting materials, and degradation during storage. All impurities must comply with pharmacopeial limits (e.g., EP, USP) and ICH Q3A/B guidelines to ensure product safety.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Roxithromycin is used to treat mild to moderate infections caused by susceptible bacteria, particularly those affecting the respiratory tract, skin, and genitourinary system.
Roxithromycin has a more favorable pharmacokinetic profile than erythromycin: it is more acid-stable, better absorbed, and has a longer half-life, allowing for less frequent dosing.
Yes. It may interact with drugs metabolized by CYP3A4 (e.g., theophylline, warfarin). However, it has fewer drug interactions than erythromycin.
It is more stable than erythromycin but can degrade under extreme pH, heat, or light conditions. Proper storage in a cool, dry place is recommended to maintain stability.
